Objective:To study the safety and efficacy of traditional Chinese medicine(TCM) dialectical treatment combination with chemotherapy in advance non-small cell lung cancer(NSCLC). Method:We searched The Cochrane Library

Pubmed

Embase

VIP

Wangfang Data

CNKI

CBM

from database inception to July5

2015.Randomized controlled trials (RCTs) of TCM dialectical treatment combination with chemotherapy in advance non-small cell lung cancer in any language were included

and recover into research references. Two researchers extracted data and assessed the literature quality separatedly

and made a Meta analysis RevMan 5.3 software. Result:The 12 RCTs involving 1341 patients entered the inclusion criteria. The Meta-analysis results showed that compared with the pure application of chemotherapy regimens

TCM dialectical treatment combination with chemotherapy can significantly improve the patients quality of life[OR=1.58

95%CI(1.03

2.42)

P=0.03]

curative effect in the near future[OR=4.38

95%CI(3.17

6.05)

P<0.00001]. Adverse reactions

TCM dialectical treatment combination with chemotherapy can reduce bone marrow suppression caused by chemotherapy (white blood cells decline[OR=0.21

95%CI(0.10

0.44)

P<0.0001]

hemoglobin decline[OR=0.29

95%CI(0.13

0.68)

P=0.004]

platelet decline[OR=0.26

95%CI(0.10

0.69)

P=0.007]

digestive tract reactions[OR=0.23

95%CI(0.09

0.63)

P=0.004]

but in the liver function damage[OR=0.37

95%CI(0.08

1.66)

P=0.19]

renal impairment[OR=0.51

95%CI(0.23

1.14)

P=0.10] were no significant differences. Conclusion:The current results indicates that TCM dialectical treatment combination with chemotherapy in advance non-small cell lung cancer can effectively improve the quality of survival

near future curative effect

reduce severe bone marrow suppression caused by chemotherapy

and gastrointestinal adverse reactions

but liver and kidney function damage and simple scheme there was no significant difference compared with chemotherapy. However

the efficacy and safety of TCM dialectical treatment combination with chemotherapy in advance non-small cell lung cancer still need more strict

large sample

randomized

double-blind trials to verify.